uBriGene (Boston) Biosciences completed the transaction with Mustang Bio, Inc. (Nasdaq: MBIO)
uBriGene (Boston) Biosciences Inc. (“uBriGene”), the U.S. subsidiary of uBriGene Group, a leading cell and gene therapy contract...
top of page
- May 18
- 3 min
Cell and Gene Therapy CDMO Targets North American Growth with Major US Acquisition
uBriGene, a cell & gene therapy contract development and manufacturing organization (CDMO), is expanding into the US market with the...
- Apr 20
- 4 min
uBriGene Biosciences Inc. closes 150 million CNY (20 million USD) Series C+ round
uBriGene Biosciences Inc. has closed a 150 million CNY (20 million USD) Series C+ financing round. It was completed just half a year...
- Dec 23, 2022
- 5 min
uBriGene Biosciences completes several hundred million yuan Series C round funding
uBriGene Biosciences completes several hundred million yuan Series C round funding, focusing on global cell & gene therapy and...
- Dec 23, 2022
- 4 min
Correcting visual impairment: VGR-R01 project IND application accepted by Center for Drug Evaluation
A VGR-R01 project IND application from uBriGene partner Vitalgen has been accepted by the CDE, aiming to correct visual impairment On...
- Apr 21, 2022
- 2 min
Assisted Clinical Application of Gene Therapy for Hemophilia B of Vitalgen Accepted by NMPA
On April 21, 2022, according to the Chinese CDE (Center for Drug Evaluation) official website, the clinical trial application of VGB-R04...
- Jan 27, 2022
- 3 min
Assisted Clinical Application of Gene Therapy in Ophthalmology of Innostellar Accepted by NMPA
On January 26, 2022, pertaining to the announcement of Chinese CDE (Center for Drug Evaluation) official website, the clinical trial...
bottom of page